Ocular Therapeutix (NASDAQ:OCUL) and United-Guardian (NASDAQ:UG) Financial Comparison

United-Guardian (NASDAQ:UG – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares United-Guardian and Ocular Therapeutix”s gross revenue, earnings per share and valuation.

United-Guardian has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United-Guardian and Ocular Therapeutix’s net margins, return on equity and return on assets.

Insider and Institutional Ownership

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

United-Guardian has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for United-Guardian and Ocular Therapeutix, as reported by MarketBeat.

Ocular Therapeutix has a consensus price target of $25.75, indicating a potential upside of 142.01%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than United-Guardian.

About United-Guardian

(Get Free Report)

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.